<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jacobson, Anne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Büller, Harry R.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">EINSTEIN DVT: Rivaroxaban Noninferior to Enoxaparin and Warfarin in Patients with DVT</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">17-17</style></pages><abstract><style  face="normal" font="default" size="100%">Treatment with rivaroxaban provided a simple, safe, and effective alternative to standard anticoagulation therapy for patients with deep vein thrombosis, according to findings from the phase III Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Deep-Vein Thrombosis Without Symptomatic Pulmonary Embolism [Einstein-DVT; NCT 00440193].</style></abstract><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">10</style></volume></record></records></xml>